AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28500087 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138
Study 28500087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (discharged within 4 hours)
Number of subjects: 138
Study 25750106 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT with breathing biofeedback
Number of subjects: 8
Study 25750106 — intervention group
Group type: COMPARATOR
Intervention: Regular TF-CBT
Number of subjects: 8
Study 23901178 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic DCR
Number of subjects: 72
Study 23901178 — intervention group
Group type: COMPARATOR
Intervention: External DCR
Number of subjects: 72
Study 21434560 — intervention group
Group type: EXPERIMENTAL
Intervention: Group health education program
Number of subjects: 628
Study 19241401 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 295
Study 19241401 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 295
Study 17098139 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 25
Study 15262833 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 3086
Study 15262833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3086
Study 11697688 — intervention group
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 9
Study 11697688 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 9
Study 9596110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuhaler primed
Number of subjects: 10
Study 9596110 — intervention group
Group type: COMPARATOR
Intervention: Nebuhaler unprimed
Number of subjects: 10
Study 9596110 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumatic primed
Number of subjects: 10
Study 9596110 — intervention group
Group type: COMPARATOR
Intervention: Volumatic unprimed
Number of subjects: 10
Study 9596110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuchamber primed
Number of subjects: 10
Study 9596110 — intervention group
Group type: COMPARATOR
Intervention: Nebuchamber unprimed
Number of subjects: 10
Study 7920958 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 120
Study 7920958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral positions (45 degrees right lateral, 45 degrees left lateral)
Number of subjects: 120
Study 7920958 — intervention group
Group type: EXPERIMENTAL
Intervention: Total group (all positions)
Number of subjects: 120
Study 7920958 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft and valve (closed or opened myocardium) subgroups
Number of subjects: 120
Study 7920958 — intervention group
Group type: COMPARATOR
Intervention: Subgroups with and without lung disease
Number of subjects: 120
Study 3402013 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 50 micrograms.kg‐1
Number of subjects: 65
Study 3402013 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 75 micrograms.kg‐1
Number of subjects: 65
Study 3402013 — intervention group
Group type: COMPARATOR
Intervention: Standard oral premedication (meperidine 1.5 mg.kg‐1, diazepam 0.15 mg.kg‐1, atropine 0.02 mg.kg‐1)
Number of subjects: 65
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmful use of alcohol
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient intake of fruit and vegetable
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and obesity
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one risk factor
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhibited six risk factors
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: At least three risk factors
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 388
Study 29855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Caste/ethnicity
Number of subjects: 388
Study 27147617 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (54 μg)
Number of subjects: 13
Study 27147617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 25786486 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) during 6 weeks
Number of subjects: 10
Study 25786486 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 10
Study 23727135 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D2 receptor occupancy levels
Number of subjects: 481
Study 23727135 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D2 receptor occupancy cut-off point
Number of subjects: 481
Study 21914315 — intervention group
Group type: EXPERIMENTAL
Intervention: Shensongyangxin capsules + propafenone 150 mg, 3 times a day
Number of subjects: 349
Study 21914315 — intervention group
Group type: COMPARATOR
Intervention: Propafenone 150 mg, 3 times a day
Number of subjects: 349
Study 18795630 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD)
Number of subjects: 0
Study 18795630 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet (HCD)
Number of subjects: 0
Study 16432682 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (50 mg)
Number of subjects: 11
Study 16432682 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 11
Study 16432682 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (3 mg)
Number of subjects: 11
Study 16432682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 12780462 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11202222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen
Number of subjects: 0
Study 11202222 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estrogen
Number of subjects: 0
Study 9175134 — intervention group
Group type: EXPERIMENTAL
Intervention: Deductive reasoning condition (determining entailment of sentences)
Number of subjects: 10
Study 9175134 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive reasoning condition (assessing plausibility of sentences)
Number of subjects: 10
Study 9175134 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive reasoning condition
Number of subjects: 10
Study 9175134 — intervention group
Group type: COMPARATOR
Intervention: Control condition (semantic comprehension of sentences)
Number of subjects: 10
Study 1544011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 0
Study 7231666 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant hemisphere damaged (DH)
Number of subjects: 0
Study 7231666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondominant hemisphere damaged (NDH)
Number of subjects: 0
Study 7231666 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 31238785 — intervention group
Group type: EXPERIMENTAL
Intervention: Student pharmacist-led telephone follow-up intervention (weekly phone calls for 12 weeks)
Number of subjects: 78
Study 31238785 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 78
Study 31157878 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Limited Formula (ELF)
Number of subjects: 164
Study 31157878 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 164
Study 28611008 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB (behavioral ED prevention program)
Number of subjects: 481
Study 28611008 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 481
Study 25273036 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 2303
Study 25273036 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 2303
Study 25273036 — intervention group
Group type: EXPERIMENTAL
Intervention: AF patients (both on-pump and off-pump)
Number of subjects: 2303
Study 24016365 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic visualization
Number of subjects: 31
Study 24016365 — intervention group
Group type: COMPARATOR
Intervention: Monoscopic visualization
Number of subjects: 31
Study 21343383 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (2.5 mg, Marinol(®), twice daily for 18 days)
Number of subjects: 46
Study 21343383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral capsules, twice daily for 18 days)
Number of subjects: 46
Study 19580960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low expressed emotion (EE) carers
Number of subjects: 70
Study 19580960 — intervention group
Group type: COMPARATOR
Intervention: High expressed emotion (EE) carers
Number of subjects: 70
Study 17382619 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional cerebral perfusion
Number of subjects: 77
Study 17382619 — intervention group
Group type: COMPARATOR
Intervention: Deep hypothermic circulatory arrest
Number of subjects: 77
Study 16832318 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmethylphenidate extended-release (d-MPH-ER)
Number of subjects: 97
Study 16832318 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97
Study 12708604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexibuprofen 800 mg daily
Number of subjects: 148
Study 12708604 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily
Number of subjects: 148
Study 12708604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Number of subjects: 148
Study 12708604 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 148
Study 10362151 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermicidal film containing 72 mg of nonoxynol-9 per film
Number of subjects: 765
Study 10362151 — intervention group
Group type: COMPARATOR
Intervention: Foaming tablet containing 100 mg of nonoxynol-9 per tablet
Number of subjects: 765
Study 7498201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory ST recordings before discharge
Number of subjects: 170
Study 7498201 — intervention group
Group type: COMPARATOR
Intervention: Symptom-limited predischarge exercise test
Number of subjects: 170
Study 1967717 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening by mammography and clinical examination
Number of subjects: 45130
Study 1967717 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening in women aged 50 years and over
Number of subjects: 45130
Study 1967717 — intervention group
Group type: COMPARATOR
Intervention: Routine mammography screening
Number of subjects: 45130
Study 1967717 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination alone as screening method
Number of subjects: 45130
Study 7042364 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (IP) 800 mg/die
Number of subjects: 102
Study 7042364 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IM) 200 mg/die
Number of subjects: 102
Study 7042364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 102
Study 7042364 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IM)
Number of subjects: 102
Study 7042364 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (IP)
Number of subjects: 102
Study 30198329 — intervention group
Group type: EXPERIMENTAL
Intervention: POD FineVision
Number of subjects: 78
Study 30198329 — intervention group
Group type: EXPERIMENTAL
Intervention: POD Toric FineVision
Number of subjects: 78
Study 30198329 — intervention group
Group type: EXPERIMENTAL
Intervention: FineVision/MicroF
Number of subjects: 78
Study 28369734 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 46
Study 26272770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg, every 3 weeks for six cycles) with neoadjuvant chemotherapy
Number of subjects: 1206
Study 26272770 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus capecitabine followed by doxorubicin plus cyclophosphamide
Number of subjects: 1206
Study 26272770 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus gemcitabine followed by doxorubicin plus cyclophosphamide
Number of subjects: 1206
Study 26272770 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone followed by doxorubicin plus cyclophosphamide
Number of subjects: 1206
Study 23852909 — intervention group
Group type: EXPERIMENTAL
Intervention: Human FSH combined with recombinant FSH (group A)
Number of subjects: 197
Study 23852909 — intervention group
Group type: COMPARATOR
Intervention: Human FSH alone (group B)
Number of subjects: 197
Study 23852909 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH alone (group C)
Number of subjects: 197
Study 21457725 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance notification letter followed by standard invitation
Number of subjects: 5000
Study 21457725 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation only
Number of subjects: 5000
Study 18643808 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity, physician-endorsed dietary intervention
Number of subjects: 754
Study 16598591 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil 200 mg t.i.d.
Number of subjects: 648
Study 16598591 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide-dinitrate (ISDN) 20 mg b.i.d.
Number of subjects: 648
Study 14600049 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Project ALERT drug prevention program (11 lessons in 7th grade and 3 in 8th grade)
Number of subjects: 4276
Study 14600049 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4276
Study 10809919 — intervention group
Group type: EXPERIMENTAL
Intervention: TGA patients, P3 latency measured at vertex (Cz electrode) in visual paradigm
Number of subjects: 18
Study 10809919 — intervention group
Group type: COMPARATOR
Intervention: TIA patients, P3 latency measured at vertex (Cz electrode) in visual paradigm
Number of subjects: 18
Study 10809919 — intervention group
Group type: COMPARATOR
Intervention: Control group, P3 latency measured at vertex (Cz electrode) in visual paradigm
Number of subjects: 18
Study 10809919 — intervention group
Group type: EXPERIMENTAL
Intervention: TGA patients, P3 latency measured at vertex (Cz electrode) in auditory paradigm
Number of subjects: 18
Study 10809919 — intervention group
Group type: COMPARATOR
Intervention: TIA patients, P3 latency measured at vertex (Cz electrode) in auditory paradigm
Number of subjects: 18
Study 10809919 — intervention group
Group type: COMPARATOR
Intervention: Control group, P3 latency measured at vertex (Cz electrode) in auditory paradigm
Number of subjects: 18
Study 8980985 — intervention group
Group type: EXPERIMENTAL
Intervention: THRESHOLD trainer
Number of subjects: 10
Study 8980985 — intervention group
Group type: COMPARATOR
Intervention: Weighted plunger (WP)
Number of subjects: 10
Study 1613700 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rtPA)
Number of subjects: 10
Study 1613700 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 6853155 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 16
Study 6853155 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 16
Study 31243022 — intervention group
Group type: EXPERIMENTAL
Intervention: Group choir singing (n=29), 90 min weekly sessions for 12 weeks
Number of subjects: 58
Study 31243022 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=29), non-intervention
Number of subjects: 58
Study 29696422 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-mouth exercise device
Number of subjects: 60
Study 29696422 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional group
Number of subjects: 60
Study 29696422 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 30421393 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol
Number of subjects: 0
Study 30421393 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 27614373 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-application practice (TAP) group
Number of subjects: 156
Study 27614373 — intervention group
Group type: COMPARATOR
Intervention: Single-application practice (SAP) group
Number of subjects: 156
Study 24263695 — intervention group
Group type: EXPERIMENTAL
Intervention: CT at 340 mAs with filtered back‐projection and sinogram‐affirmed iterative reconstruction (S1-S5)
Number of subjects: 94
Study 24263695 — intervention group
Group type: COMPARATOR
Intervention: CT at 260 mAs with filtered back‐projection and sinogram‐affirmed iterative reconstruction (S1-S5)
Number of subjects: 94
Study 22616576 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm based on administrative data with three criteria: a) discharged patients with a chronic lung-disease diagnosis at least once during the preceding 5 years; b) redeemed prescription of lung-medication at least twice during the preceding 12 months; c) at least two spirometries performed at different dates during the preceding 12 months.
Number of subjects: 266
Study 22616576 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm based on administrative data.
Number of subjects: 266
Study 20615491 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming for innovativeness
Number of subjects: 0
Study 20615491 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming involving additional AA-relevant dimensions
Number of subjects: 0
Study 20615491 — intervention group
Group type: COMPARATOR
Intervention: No specific control group mentioned
Number of subjects: 0
Study 17437872 — intervention group
Group type: EXPERIMENTAL
Intervention: RoekoSeal (silicone‐based)
Number of subjects: 95
Study 17437872 — intervention group
Group type: EXPERIMENTAL
Intervention: AH‐Plus (epoxy‐resin‐based)
Number of subjects: 95
Study 17437872 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth's sealer (zinc oxide eugenol‐based)
Number of subjects: 95
Study 15224025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g as 20-minute bolus before skin incision, followed by continuous infusion of 400 mg/h, with 500 mg added to priming in on-pump patients)
Number of subjects: 102
Study 15224025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution of equivalent volume)
Number of subjects: 102
Study 15224025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 102
Study 11759645 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 5010
Study 11759645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5010
Study 9399611 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist intervention
Number of subjects: 51
Study 9399611 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 7708529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptorchid patients
Number of subjects: 517
Study 7708529 — intervention group
Group type: COMPARATOR
Intervention: Control group (boys who underwent inguinal exploration)
Number of subjects: 517
Study 7708529 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults operated on for bilateral cryptorchidism
Number of subjects: 517
Study 3502173 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% flurbiprofen
Number of subjects: 72
Study 3502173 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 72
Study 29798889 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 8309
Study 29798889 — intervention group
Group type: COMPARATOR
Intervention: White participants
Number of subjects: 8309
Study 29798889 — intervention group
Group type: COMPARATOR
Intervention: Black participants vs White participants
Number of subjects: 8309
Study 27062948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 24
Study 27062948 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment as usual, delayed treatment (DT) control
Number of subjects: 24
Study 25690404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed RF EMF exposure (900 MHz, 2 Hz pulse, 20 Hz Gaussian low-pass filter, spatial peak absorption of 2 W/kg averaged over 10 g) for 30 minutes prior to sleep
Number of subjects: 20
Study 23615825 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-15 g alcohol/d (about one drink)
Number of subjects: 93676
Study 23615825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative average alcohol intake
Number of subjects: 93676
Study 23615825 — intervention group
Group type: EXPERIMENTAL
Intervention: Most recent alcohol intake
Number of subjects: 93676
Study 23615825 — intervention group
Group type: COMPARATOR
Intervention: Total caffeine intake, cups of caffeinated coffee, decaffeinated coffee, and caffeinated tea
Number of subjects: 93676
Study 20948487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent catheterization
Number of subjects: 75
Study 20948487 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic catheterization
Number of subjects: 75
Study 19026794 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimount valve
Number of subjects: 99
Study 19026794 — intervention group
Group type: COMPARATOR
Intervention: Mosaic valve
Number of subjects: 99
Study 19026794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both valves
Number of subjects: 99
Study 16799824 — intervention group
Group type: EXPERIMENTAL
Intervention: Telos device
Number of subjects: 30
Study 16799824 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring contraction
Number of subjects: 30
Study 16799824 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling view
Number of subjects: 30
Study 16799824 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity view
Number of subjects: 30